Published in BMJ on October 15, 2005
Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol (2006) 1.13
Should we really worry about "launch delays" of new drugs in OECD countries? Eur J Health Econ (2007) 0.96
Toward a definition of pharmaceutical innovation. Open Med (2008) 0.85
The Italian Horizon Scanning Project. Eur J Clin Pharmacol (2009) 0.84
Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents. Retrovirology (2007) 0.78
EMA's reflection on placebo does not reflect patients' interests. Eur J Clin Pharmacol (2011) 0.78
How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012. BMJ Open (2014) 0.75
Disappointing article, not disappointing biotech. BMJ (2005) 0.75
Do we learn the right things from clinical trials? Eur J Clin Pharmacol (2008) 0.75
Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med (2001) 6.94
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis (2003) 4.53
New drugs for rheumatoid arthritis. N Engl J Med (2004) 4.38
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet (1996) 2.20
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 2.12
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood (2001) 1.86
Clinical cardiac tolerability of trastuzumab. J Clin Oncol (2004) 1.43
Are me-too drugs justified? J Nephrol (1998) 0.95
Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol (2001) 0.92
Non-inferiority trials are unethical because they disregard patients' interests. Lancet (2007) 4.72
Rare diseases: what's next? Lancet (2008) 3.06
Smoking in Italy 2005-2006: effects of a comprehensive National Tobacco Regulation. Prev Med (2007) 2.61
Orphan drug development is not taking off. Br J Clin Pharmacol (2009) 2.27
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res (2010) 2.21
Orphan drug development is progressing too slowly. Br J Clin Pharmacol (2006) 1.79
Europe's opportunity to open up drug regulation. BMJ (2010) 1.71
Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis (2009) 1.55
Ethics in clinical research. J Hepatol (2009) 1.54
Anything new in EU pharmacovigilance? Eur J Clin Pharmacol (2011) 1.53
Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach? Acta Psychiatr Scand (2006) 1.42
Varying and "atypical" indications for atypical antipsychotics. Psychopharmacology (Berl) (2003) 1.40
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol (2012) 1.39
Italy must invest more in science and technology. Nature (2008) 1.38
Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol (2003) 1.11
Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol (2003) 1.10
Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol (2008) 0.99
How can we regulate medicines better? BMJ (2007) 0.98
Reconsidering the Declaration of Helsinki. Lancet (2013) 0.98
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol (2006) 0.95
A failed attempt at collaboration. BMJ (2013) 0.92
Fluoxetine dose and outcome in antidepressant drug trials. Eur J Clin Pharmacol (2002) 0.90
A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med (2007) 0.89
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res (2014) 0.87
Withdrawal of 'Xigris' from the market: old and new lessons. J Epidemiol Community Health (2012) 0.86
Pre-market clinical evaluations of innovative high-risk medical devices in Europe. Int J Technol Assess Health Care (2012) 0.86
Drug sales in four European countries still differ. BMJ (2003) 0.85
Flaws in animal studies exploring statins and impact on meta-analysis. Eur J Clin Invest (2014) 0.84
Regulatory policies on medicines for psychiatric disorders: is Europe on target? Br J Psychiatry (2007) 0.84
Thrombolysis or nothing for acute myocardial infarction? It's all the same! Br J Clin Pharmacol (2008) 0.84
Independent clinical research in Europe. Lancet (2004) 0.83
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.82
Haematological anticancer drugs in Europe: any added value at the time of approval? Eur J Clin Pharmacol (2007) 0.82
New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol (2007) 0.82
Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey. PLoS One (2012) 0.82
Most appropriate animal models to study the efficacy of statins: a systematic review. Eur J Clin Invest (2014) 0.81
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics (2008) 0.81
Rosiglitazone and the need for a new drug safety agency. BMJ (2010) 0.80
Europe also needs agency for postmarketing surveillance. BMJ (2005) 0.80
European regulatory policies on medicines and public health needs. Eur J Public Health (2003) 0.80
Predicting the clinical relevance of drug interactions from pre-approval studies. Drug Saf (2009) 0.79
New drugs for thromboprophylaxis in atrial fibrillation. Eur J Intern Med (2011) 0.79
EMA's reflection on placebo does not reflect patients' interests. Eur J Clin Pharmacol (2011) 0.78
CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology (Berl) (2006) 0.78
Time to revisit the orphan drug law. Eur J Clin Pharmacol (2011) 0.78
Bevacizumab and ranibizumab. A matter of public interest. BMJ (2010) 0.77
A new anti-cancer drug in the market: Good news for investors or for patients? Eur J Cancer (2008) 0.77
Confidentiality. Lancet (2003) 0.77
Ethics of testing drugs with readily available alternatives. Lancet (2002) 0.75
Antibiotics versus surgery for appendicitis. Lancet (2011) 0.75
Is there discrimination in access to therapy for HCV patients? J Hepatol (2008) 0.75
Cetuximab for metastatic colorectal cancer. N Engl J Med (2009) 0.75
Effects of physical inactivity on non-communicable diseases. Lancet (2012) 0.75
Alternative medical practices: flashbacks from the Dark Ages. Eur J Intern Med (2010) 0.75
Discontinuation of Vioxx. Lancet (2005) 0.75
Dutasteride and prostate cancer. N Engl J Med (2010) 0.75
Controlling cervical cancer. Pharmacoeconomics (2009) 0.75
Informed consent: meet patients' needs. Nature (2012) 0.75
Exenatide for type 2 diabetes. Lancet (2009) 0.75
Use of cigarette vending machines by minors in Italy. Int J Epidemiol (2004) 0.75
The European Commission should require better medicines, not just faster reimbursements. Eur J Intern Med (2012) 0.75
[False innovations in clinical research]. Recenti Prog Med (2006) 0.75
Ethics committees in Italy: a survey on a sample of oncologists. Tumori (2003) 0.75
The scientific community should lobby to be able to apply for drug licences. BMJ (2012) 0.75
Limits of add-on trials: antirheumatic drugs. Eur J Clin Pharmacol (2008) 0.75
European Council waters down European Parliament's drug-regulatory legislation. Lancet (2003) 0.75
[Effects of new smoking regulations in Italy]. Salud Publica Mex (2006) 0.75
Targeted kinase inhibitors in lung cancer: from EGFR to patients. Eur J Cancer (2005) 0.75
Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure. Eur J Clin Pharmacol (2007) 0.75
The impact of European regulatory policies on psychotropic drug prescribing patterns. Int Rev Psychiatry (2005) 0.75
Sparing animals and progressing in science. Trends Pharmacol Sci (2003) 0.75
Italy: court's expert panel condemns tobacco. Tob Control (2002) 0.75
Do we learn the right things from clinical trials? Eur J Clin Pharmacol (2008) 0.75
[A model for integrating biomedical research information]. Recenti Prog Med (2004) 0.75
[Considerations on clinical drug research in Italy]. G Ital Cardiol (Rome) (2006) 0.75
Light and shade in proposed revision of EU drug-regulatory legislation. Lancet (2003) 0.75
EMEA: for patients or for industry? Pharmacoeconomics (2005) 0.75
Clinical trial registries: from an omen to a common and disclosed practice. Eur J Clin Pharmacol (2013) 0.75
Toward new legislation on drugs in Europe. Expert Rev Pharmacoecon Outcomes Res (2002) 0.75
[Great discoveries: from the painstaking efforts of researchers to the contribution of accidental findings and the dissemination of study results]. Recenti Prog Med (2015) 0.75
Clinical databases of patients receiving antidepressants. The missing link between research and practice? J Affect Disord (2002) 0.75